FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074443395> ?p ?o ?g. }

• W2074443395 endingPage "141" @default.
• W2074443395 startingPage "135" @default.
• W2074443395 abstract "A novel composite endpoint, sustained pain-free/no adverse events, was recently proposed as a more rigorous means of capturing in a single measure the attributes of migraine pharmacotherapy that patients consider most important: rapid and sustained pain-free response with no side-effects. Using pooled data from two replicate randomized, double-blind, parallel-group, placebo-controlled studies, this post hoc analysis compared the fixed-dose combination tablet sumatriptan/naproxen sodium (n = 726) with sumatriptan monotherapy (n = 723), naproxen sodium monotherapy (n = 720), and placebo (n = 742) with respect to sustained pain-free/no adverse events and closely related composite measures. Sustained pain-free/no adverse events was defined as having both a sustained pain-free response from 2 through 24 hours post-dose with no use of rescue medication and having no adverse events within up to 5 days after dosing with study medication. The percentage of patients with sustained pain-free/no adverse events was 16% with sumatriptan/naproxen sodium compared with 11%, 9% and 7% for sumatriptan, naproxen sodium and placebo, respectively (p<0.01 sumatriptan/naproxen sodium versus each other treatment). Sumatriptan/naproxen sodium was also significantly more effective than sumatriptan, naproxen sodium, and placebo for other composite endpoints including the percentages of patients with (1) sustained pain-free/no adverse events within 1 day; (2) sustained pain-free/no drug-related adverse events within up to 5 days; (3) sustained pain-free/no drug-related adverse events within 1 day; (4) sustained pain relief/no adverse events within up to 5 days; and (5) sustained pain relief/no adverse events within 1 day. The results demonstrate the superiority of sumatriptan/naproxen sodium to sumatriptan monotherapy, naproxen sodium monotherapy and placebo with respect to the rigorous and clinically relevant endpoint of sustained pain-free/no adverse events and reinforce the usefulness of utilizing this new composite endpoint." @default.
• W2074443395 created "2016-06-24" @default.
• W2074443395 creator A5006365150 @default.
• W2074443395 creator A5039854081 @default.
• W2074443395 creator A5060098219 @default.
• W2074443395 creator A5082980079 @default.
• W2074443395 date "2009-04-30" @default.
• W2074443395 modified "2023-09-26" @default.
• W2074443395 title "Fixed-dose sumatriptan/naproxen sodium compared with each monotherapy utilizing the novel composite endpoint of sustained pain-free/no adverse events" @default.
• W2074443395 cites W1963565798 @default.
• W2074443395 cites W1997546418 @default.
• W2074443395 cites W2003163400 @default.
• W2074443395 cites W2005128914 @default.
• W2074443395 cites W2013563301 @default.
• W2074443395 cites W2036921167 @default.
• W2074443395 cites W2041898141 @default.
• W2074443395 cites W2048461020 @default.
• W2074443395 cites W2056317944 @default.
• W2074443395 cites W2058027543 @default.
• W2074443395 cites W2073074795 @default.
• W2074443395 cites W2081973571 @default.
• W2074443395 cites W2104400722 @default.
• W2074443395 cites W2126194551 @default.
• W2074443395 cites W2136100212 @default.
• W2074443395 cites W2139670360 @default.
• W2074443395 cites W2157484161 @default.
• W2074443395 cites W2164536330 @default.
• W2074443395 doi "https://doi.org/10.1177/1756285609102769" @default.
• W2074443395 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3002629" @default.
• W2074443395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21179523" @default.
• W2074443395 hasPublicationYear "2009" @default.
• W2074443395 type Work @default.
• W2074443395 sameAs 2074443395 @default.
• W2074443395 citedByCount "9" @default.
• W2074443395 countsByYear W20744433952013 @default.
• W2074443395 countsByYear W20744433952016 @default.
• W2074443395 countsByYear W20744433952021 @default.
• W2074443395 crossrefType "journal-article" @default.
• W2074443395 hasAuthorship W2074443395A5006365150 @default.
• W2074443395 hasAuthorship W2074443395A5039854081 @default.
• W2074443395 hasAuthorship W2074443395A5060098219 @default.
• W2074443395 hasAuthorship W2074443395A5082980079 @default.
• W2074443395 hasBestOaLocation W20744433952 @default.
• W2074443395 hasConcept C126322002 @default.
• W2074443395 hasConcept C142724271 @default.
• W2074443395 hasConcept C168563851 @default.
• W2074443395 hasConcept C170493617 @default.
• W2074443395 hasConcept C197934379 @default.
• W2074443395 hasConcept C203092338 @default.
• W2074443395 hasConcept C204787440 @default.
• W2074443395 hasConcept C27081682 @default.
• W2074443395 hasConcept C2776312127 @default.
• W2074443395 hasConcept C2778115740 @default.
• W2074443395 hasConcept C2778541695 @default.
• W2074443395 hasConcept C2778871607 @default.
• W2074443395 hasConcept C2778938600 @default.
• W2074443395 hasConcept C2909752691 @default.
• W2074443395 hasConcept C2991744798 @default.
• W2074443395 hasConcept C42219234 @default.
• W2074443395 hasConcept C71924100 @default.
• W2074443395 hasConcept C98274493 @default.
• W2074443395 hasConceptScore W2074443395C126322002 @default.
• W2074443395 hasConceptScore W2074443395C142724271 @default.
• W2074443395 hasConceptScore W2074443395C168563851 @default.
• W2074443395 hasConceptScore W2074443395C170493617 @default.
• W2074443395 hasConceptScore W2074443395C197934379 @default.
• W2074443395 hasConceptScore W2074443395C203092338 @default.
• W2074443395 hasConceptScore W2074443395C204787440 @default.
• W2074443395 hasConceptScore W2074443395C27081682 @default.
• W2074443395 hasConceptScore W2074443395C2776312127 @default.
• W2074443395 hasConceptScore W2074443395C2778115740 @default.
• W2074443395 hasConceptScore W2074443395C2778541695 @default.
• W2074443395 hasConceptScore W2074443395C2778871607 @default.
• W2074443395 hasConceptScore W2074443395C2778938600 @default.
• W2074443395 hasConceptScore W2074443395C2909752691 @default.
• W2074443395 hasConceptScore W2074443395C2991744798 @default.
• W2074443395 hasConceptScore W2074443395C42219234 @default.
• W2074443395 hasConceptScore W2074443395C71924100 @default.
• W2074443395 hasConceptScore W2074443395C98274493 @default.
• W2074443395 hasIssue "3" @default.
• W2074443395 hasLocation W20744433951 @default.
• W2074443395 hasLocation W20744433952 @default.
• W2074443395 hasLocation W20744433953 @default.
• W2074443395 hasLocation W20744433954 @default.
• W2074443395 hasOpenAccess W2074443395 @default.
• W2074443395 hasPrimaryLocation W20744433951 @default.
• W2074443395 hasRelatedWork W1985762969 @default.
• W2074443395 hasRelatedWork W2007237080 @default.
• W2074443395 hasRelatedWork W2017859904 @default.
• W2074443395 hasRelatedWork W2019660771 @default.
• W2074443395 hasRelatedWork W2020900211 @default.
• W2074443395 hasRelatedWork W2022556905 @default.
• W2074443395 hasRelatedWork W2033450638 @default.
• W2074443395 hasRelatedWork W2045971834 @default.
• W2074443395 hasRelatedWork W2074443395 @default.
• W2074443395 hasRelatedWork W4251165208 @default.
• W2074443395 hasVolume "2" @default.
• W2074443395 isParatext "false" @default.

• next